Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
784
datasets available to search
ShareScore release 0.9.0
Dataset results
784 results for “CNS”
Next Generation Sequencing of CNS-infiltrating Tox-sufficient and -deficient OT-1 cells in ODC-OVA mice 7 days after LCMV-OVA infection
GEO Series GSE93804. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Transcriptome analysis of CNS and splenic FOXP3+ Tregs vs. exFOXP3 T cells during EAE
GEO Series GSE255607. Mus musculus. 1 samples. Type: Expression profiling by high throughput sequencing.
p38 MAP kinase signaling in microglia plays a sex-specific protective role in CNS autoimmunity and regulates microglial transcriptional states [male]
GEO Series GSE185044. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Disruption of DNA methylation underpins the neuroinflammation induced by targeted CNS radiotherapy
GEO Series GSE289218. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS
GEO Series GSE31560. Mus musculus. 6 samples. Type: Expression profiling by array.
RNA sequencing - Microglial A20 is a critical gatekeeper of CNS homeostasis
GEO Series GSE123033. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Data from: Management and outcome of primary CNS lymphoma patients in the modern era. a LOC network study
Objective: Studies on primary CNS lymphoma (PCNSL) patients in the "real life" are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice in the management of PCNSL. Methods: The LOC database prospectively records all newly diagnosed PCNSL from 32 French centers. Data of patients diagnosed between 2011-2016 were retrospectively analyzed. Results: We identified 1002 immunocompetent patients (43% aged>70 years, median KPS 60). First-line treatment was high-dose methotrexate-based chemotherapy in 92% of cases, with an increasing use of rituximab over time (66%). Patients <60 years old received consolidation treatment in 77% of cases, consisting of whole-brain radiotherapy (WBRT) (54%) or high-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) (23%). Among the patients > 60 years old, WBRT and HCT-ASCT consolidation were administered in only 9% and 2%, respectively. The complete response rate to initial chemotherapy was 50%. Median progression-free survival was 10.5 months. For relapse, second-line chemotherapy, HCT-ASCT, WBRT and palliative care were offered to 55%, 17%, 10%, and 18% of patients, respectively. The median, 2-year and 5-year overall survival was 25.3 months, 51% and 38%, respectively (< 60 years: not reached (NR), 70% and 61%; > 60 years: 15.4 months, 44% and 28%). Age, KPS, sex and response to induction CT were independent prognostic factors in multivariate analysis. Conclusions: Our study confirms the increasing proportion of elderly within PCNSL and shows comparable outcome in this population-based study with those reported by clinical trials, reflecting a notable application of recent PCNSL advances in the real life.
Data from: Exploratory proteomic analysis implicates the alternative complement cascade in Primary CNS Vasculitis
Objective: To identify molecular correlates of primary angiitis of the central nervous system (PACNS) through proteomic analysis of cerebrospinal fluid (CSF) from a biopsy-proven patient cohort. Methods: Using mass spectrometry, the CSF proteome of biopsy-proven PACNS patients (n=8) was quantitatively compared to CSF from individuals with non-inflammatory conditions (n=11). Significantly enriched molecular pathways were identified using a gene ontology workflow, and high confidence hits within enriched pathways (fold change >1.5 and concordant Benjamini-Hochberg-adjusted p-value <0.05 on DeSeq and t-test) were identified as differentially regulated proteins. Results: Compared to non-inflammatory controls, 283 proteins were differentially expressed in PACNS patient CSF, with significant enrichment of the complement cascade pathway (C4-binding protein, CD55, CD59, properdin, complement C5, complement C8 and complement C9) and neural cell adhesion molecules. A subset of clinically relevant findings was validated by western blot and commercial ELISA. Conclusions: In this exploratory study we found evidence of deregulation of the alternative complement cascade in CSF from biopsy-proven PACNS as compared to non-inflammatory controls. More specifically, several regulators of the C3 and C5 convertases and components of the terminal cascade were significantly altered. These preliminary findings shed light on a previously unappreciated similarity between PACNS and systemic vasculitides, especially Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. The therapeutic implications of this common biology, and the diagnostic and/or therapeutic utility of individual proteomic findings warrant validation in larger cohorts.
Supplementary Video 1 of: Ultra-fast deep-learned CNS tumor classification during surgery
<p><strong>Supplementary Video 1:</strong> An intraoperative sequencing experiment (INTRA_4) was captured on film. Audio has been redacted for privacy reasons. The timeline of this specific experiment is shown as a representative example in Fig. 4.</p>
Specialized astrocytes mediate glutamatergic gliotransmission in the CNS
<ul> <li>"iGluSnFRanalysis.7z" is a zip file containing two distinct sub-folders called "invivo" and "exvivo" data contains analysis tools to reproduce iGluSnFR datasets presented in Figure2. Each folder contain specific ReadMe file to explain step-by-step how to perform the analysis.</li> <li>"transcriptomic_analysis.tar.xz" is an archive file containg R project including all the scripts and data to reproduce the analysis</li> </ul> <p> </p> <p> </p>
Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT00862173. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours
ClinicalTrials.gov study NCT04109131. IPD Sharing: Not stated. Countries: 3. Publications: 0.
A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)
ClinicalTrials.gov study NCT03685500. IPD Sharing: NO. Countries: 1. Publications: 0.
Whole Body Metabolism in Children Before and After Treatment of CNS Tumor
ClinicalTrials.gov study NCT06380387. IPD Sharing: NO. Countries: 1. Publications: 0.
Exercise Study in Brain and CNS Cancer
ClinicalTrials.gov study NCT05531695. IPD Sharing: Not stated. Countries: 1. Publications: 0.
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
ClinicalTrials.gov study NCT02875314. IPD Sharing: UNDECIDED. Countries: 3. Publications: 0.
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
ClinicalTrials.gov study NCT05681195. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
ClinicalTrials.gov study NCT03212807. IPD Sharing: NO. Countries: 1. Publications: 0.
Mapping Draining Lymph Nodes in CNS Malignancies
ClinicalTrials.gov study NCT04096716. IPD Sharing: NO. Countries: 1. Publications: 0.
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
ClinicalTrials.gov study NCT06876688. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.